ORIC Stock Overview
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ORIC Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.19 |
| 52 Week High | US$16.65 |
| 52 Week Low | US$4.89 |
| Beta | 1.03 |
| 1 Month Change | -36.00% |
| 3 Month Change | -8.28% |
| 1 Year Change | 70.19% |
| 3 Year Change | -60.29% |
| 5 Year Change | n/a |
| Change since IPO | -64.34% |
Recent News & Updates
Recent updates
ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains
Mar 13We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate
Jan 18
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Sep 27ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 14Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
Jan 24ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech
Oct 14Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?
Oct 08ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09
Aug 11ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 24We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Mar 08We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Nov 23We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Aug 05ORIC Pharmaceuticals EPS beats by $0.04
May 06Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation
Apr 16We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Jan 01
Oric Pharma starts expansion phase of mid-stage solid tumor study with ORIC-101
Dec 21Oric Pharma prices stock offering at $23
Nov 13Shareholder Returns
| ORIC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.2% | -4.7% | -3.7% |
| 1Y | 70.2% | -2.7% | 20.2% |
Return vs Industry: ORIC exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: ORIC exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| ORIC volatility | |
|---|---|
| ORIC Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ORIC's share price has been volatile over the past 3 months.
Volatility Over Time: ORIC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 100 | Jacob Chacko | www.oricpharma.com |
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers.
ORIC Pharmaceuticals, Inc. Fundamentals Summary
| ORIC fundamental statistics | |
|---|---|
| Market cap | US$640.74m |
| Earnings (TTM) | -US$100.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.1x
P/E RatioIs ORIC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORIC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$100.70m |
| Earnings | -US$100.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.49 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ORIC perform over the long term?
See historical performance and comparison